

# DCRI Think Tank Roundtable Meetings

2000 – 2004

## 2004

### **Combination Pills in Cardiovascular Disease: Update and Future Ideas**

October 7-9, 2004

Directors: Robert Califf, MD, George Bakris, MD

### **Child and Adolescent Psychopharmacology in the New Millennium: A Workshop for Academia, Industry and Government**

September 23-25, 2004

Directors: Joseph DeVeauugh-Geiss, MD, John March, MD, Barry Mangum, PharmD

[Child and Adolescent Psychopharmacology in the New Millennium: A Workshop for Academia, Industry and Government](#)

JAACAP 45:3 March 2006, 261-270.

### **ICD-CRT**

August 23-24, 2004

Directors: Robert Califf, MD, Sana Al-Khatib, MD, Gillian Sanders, PhD

[Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004.](#)

Am Heart J 2005; 149:1020-34

### **Post-Market Evaluation of Breakthrough Technology Summit on Issues and Approaches (Case Study on DES Thrombosis & Allergy)**

February 16-18, 2004

Directors: Robert Califf, MD, Mitch Krucoff, MD, Carl Pepine

Hosted By: Duke Clinical Research Institute and American College of Cardiology Foundation (ACCF Heart House, Bethesda, MD)

### **Type 2 Diabetes, the Metabolic Syndrome and Adult Obesity: Evolving the Paradigms**

January 29-31, 2004

Directors: Scott Grundy, MD, Darren McGuire, MD

### **Heart Failure Trial Endpoints: Where are we heading?**

January 22-24, 2004

Directors: Christopher O'Connor, MD, Peter Carson, MD

## 2003

### **Genetics of Cardiovascular Disease II**

September 12-13, 2003

Directors: Christopher Granger, MD, Pascal Goldschmidt, MD, and Eric Topol, MD

### **Liability issues for data monitoring committee members**

January 16-18, 2003

Directors: David DeMets, PhD, Thomas Fleming, PhD

[Liability issues for data monitoring committee members.](#)

Clinical Trials 2004;1:525.

## 2002

### **Registration/approval/coverage/payment, Exploring Options for Improving Healthcare**

December 8-9, 2002

Directors: Kevin Schulman, MD, Daniel Mark, MD, Daniel Mendelson

[Exploring options for improving healthcare.](#)

Am Heart J. 2004 Jan; 147(1):23-30.

### **Challenges in Designing Trials of Drug-Eluting Stents**

July 28-30, 2002

Directors: Robert M. Califf, MD, Richard Kuntz, MD, James P. Zidar, MD

### **How to Develop Drug Combinations**

July 19-21, 2002

Director: Robert M. Califf, MD

### **Update on Key Issues in Phase III Cardiovascular Trial Design (Active Controls and Biomarker Surrogates)**

May 22-24, 2002

Directors: Robert Califf, MD, David DeMets, PhD, Thomas Fleming, PhD, Magnus Ohman, MD

### **Uncontrolled Systolic Hypertension**

April 26-27, 2002

Directors: Robert M. Califf, MD, Henry Black, MD  
[Results of expert meetings. Uncontrolled systolic hypertension Washington, DC, April 25-27, 2002](#)

AHJ 2005, 149(5):768

[Systolic hypertension: An overview](#)

AHJ 2005, 149(5):769-75,

[Evaluation and management of patients with uncontrolled systolic hypertension: Is another new paradigm really needed?](#)

AHJ 2005, 149(5):776-84.

[Barriers to Hypertension control](#)

AHJ 2005, 149(5):785-794

[Improving blood pressure control by tailored feedback to patients and clinicians](#)

AHJ 2005, 149(5):795-803

[Diet and blood pressure: Applying the evidence to clinical practice](#)

AHJ 2005, 149(5):804-12;

### **The Metabolic Syndrome of Cardiovascular Risk and Insulin Resistance**

April 18-20, 2002

Directors: John Guyton, MD, Ralph A. DeFronzo, MD, Robert M. Califf, MD

[Metabolic syndrome: definition, pathophysiology, and mechanisms.](#)

AHJ 2005, 149(1):33-45;

[Metabolic syndrome: evaluation of pathological and therapeutic outcomes.](#)

AHJ 2005, 149(1):20-32

**"Back to our Future" How Government, Industry and Academia Can Work Together to Improve Pediatric Clinical Research**

April 11-13, 2002

Directors: Stephen Sanders, MD, Jennifer Li, MD, Robert M. Califf, MD

**Depression and Cardiovascular Disease**

January 24-26, 2002

Directors: Christopher O'Connor, MD, Ranga Krishnan, MD, Alexander Glassman, MD, Robert M. Califf, MD

[Depression and ischemic heart disease: what have we learned so far and what must we do in the future?](#)

AHJ 2005, 150:54-78

**2001**

**Challenges in Ethically Designing Trials of Therapy for Peripheral Vascular Disease**

November 29-December 1, 2001

Directors: George J. Agich, PhD, Kenneth Ouriel, MD.

**24-Hour Ambulatory Blood Pressure Monitoring**

July 19-21, 2001

Directors: Robert M. Califf, MD, Raymond Lipicky, MD

[24-hour ambulatory blood pressure monitoring.](#)

AHJ 2006 May, 151(5):962-8

**International Differences in Clinical Trials Conduct and Results**

June 29 – 30, 2001,

Director: Robert M. Califf, MD

**Practical Issues in the Non-ST Elevation ACS Guidelines**

May 18-20, 2001

Directors: Robert M. Califf, MD, Magnus Ohman, MD, FACC

**Decompensated Heart Failure: Current Concepts and Future Directions**

April 20-22, 2001

Directors: Mihai Gheorghiade, MD, Robert M. Califf, MD, Christopher M. O'Connor, MD

[Abstract](#)

Am Heart J 2003; 145:S1-2

[Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization](#)

Am Heart J 2003; 145:S3-17

[The problem of decompensated heart failure: Nomenclature, classification, and risk stratification](#)

Am Heart J 2003; 145:S18-25

[Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure](#)

Am Heart J 2003; 145:S26-33

[B-Type natriuretic peptide: From bench to bedside](#)

Am Heart J 2003; 145:S34-46

[Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure](#)

Am Heart J 2003; 145:S47-50

[Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure](#)

Am Heart J 2003; 145:S51-4

[Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure \(PRESERVD-HF\)](#)

Am Heart J 2003; 145:S55-7

[Tezosentan in patients with acute heart failure and acute coronary syndromes: Design of the fourth Randomized Intravenous Tezosentan Study \(RITZ-4\)](#)

Am Heart J 2003; 145:S58-9

[Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure \(IMPACT-HF\) study](#)

Am Heart J 2003; 145:S60-1

[Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of  \$\beta\$ -blocker therapy in patients with heart failure: A proposal for a trial](#)

Am Heart J 2003; 145:S62-6

[Surrogate end points in heart failure trials](#)

Am Heart J 2003; 145:S67-70.

**Reducing Costs of Phase III Clinical Trials**

March 29-31, 2001, Washington, D.C.

Directors: Robert M. Califf, MD, Eric L. Eisenstein, DBA

[Reducing the costs of phase III cardiovascular clinical trials](#)

Am Heart J 2005; 149:482-8.

**The Nexus of Cardiovascular and Renal Disease**

February 23-25, 2001, Washington, DC

Directors: William F. Owen, Jr., MD, Robert M. Califf, MD, William F. Keane, MD

**Changing Diagnosis of Acute Myocardial Infarctions – Implications for Practicing Clinical Investigations**

January 25-27, 2001, Washington, D.C.

Directors: Magnus Ohman, MD, FACC, Joseph S. Alpert, MD

[Things ain't what they used to be: Impact of a new definition of myocardial infarction](#)

AHJ 2002, 144: S933-S937;

[Changing the diagnosis of acute myocardial infarction: Implications for practice and clinical investigations](#)

AHJ 2002, 144: S957-S980

[European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials](#)

AHJ 2002, 144: S981-S986

## 2000

### **Risk Stratification and Interventions to Attenuate Progressive Diabetic Nephropathy**

November 3-5, 2000, Washington, DC

Directors: William F. Owen, Jr., MD, George L. Bakris, MD

[Slowing the progression of diabetic nephropathy and its cardiovascular consequences](#)

AHJ 2004, 148(2):243-51

### **Cardiac Repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management**

August 9-11, 2000

Directors: Robert M. Califf, MD, Dan M. Roden, MDCM

[Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management](#)

AHJ 2000:144:S769-S781

### **Institutional Review Boards & Data & Safety Monitoring Committees in the Monitoring of Clinical Trials**

May 11-12, 2000

Directors: Robert M. Califf, MD, Jeremy Sugarman, MD, Donald F. Fortin, MD

### **Cardiovascular Effects of Obesity & Obesity Treatment**

March 24-26, 2000

Director: Robert M. Califf, MD

[Introduction: Cardiologists should target obesity](#)

Am Heart J 2001; 142:1088-90.

[Obesity as a disease entity](#)

Am Heart J 2001; 142:1091-4.

[Obesity assessment](#)

Am Heart J 2001; 142:1095-101

[Obesity as a risk factor in coronary artery disease](#)

Am Heart J 2001; 142:1102-7.

[Obesity, the metabolic syndrome, and cardiovascular disease](#)

Am Heart J 2001; 142:1108-16.

### **Neuroprotection in Acute Cerebral Ischemia**

February 25-27, 2000

Directors: S. Clifford Schold, MD, James Grotta, MD